Abstract: The invention provides a number of strategies for transferring and/or evolving gene(s) associated with cellular DNA uptake so that they confer or enhance DNA-uptake capacity of a recipient cell. Evolution is achieved by recursive cycles of recombination and screening/selection. One such strategy entails evolving genes that confer competence in one species to confer either greater competence in that species, or comparable or greater competence in a second species. Another strategy entails evolving genes for use as components of cloning vector to confer enhanced uptake of the vector. Other strategies entail evolving viral receptors, viruses, and genes that mediate conjugal transfer.
Abstract: The invention provides methods for screening libraries of complexes for compounds having a desired property, especially, the capacity to agonize, bind to, or antagonize a cellular receptor. The complexes in such libraries comprise a compound under test, a tag recording at least one step in synthesis of the compound, and a tether susceptible to modification by a reporter molecule. Modification of the tether is used to signify that a complex contains a compound having a desired property. The tag can be decoded to reveal at least one step in the synthesis of such a compound.
Type:
Grant
Filed:
December 3, 1996
Date of Patent:
September 28, 1999
Assignee:
Glaxo Group Limited
Inventors:
William J. Dower, Gregory L. Heinkel, Larry Mattheakis, Peter J. Schatz
Abstract: Biotinylation peptides can be fused to other peptides or proteins of interest using recombinant DNA techniques to provide efficient methods for biotinylating the resulting fusion proteins in vivo or in vitro.
Abstract: A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a fusion protein comprised of a DNA binding protein and a random peptide and also encode a binding site for the DNA binding protein can be used to screen for novel ligands. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand and to the recombinant DNA vector through the DNA binding protein.
Type:
Grant
Filed:
October 26, 1995
Date of Patent:
March 31, 1998
Assignee:
Affymax Technologies N.V.
Inventors:
Peter J. Schatz, Millard G. Cull, Jeff F. Miller, Willem Peter Christiaan Stemmer, Christian M. Gates
Abstract: Peptides which bind to selected receptor molecules are identified by screening libraries which encode a random or controlled collection of amino acids. Peptides encoded by the libraries are expressed as fusion proteins of bacteriophage coat proteins, and bacteriophage particles are then screened against the receptors of interest. Peptides having a wide variety of uses, such as therapeutic or diagnostic reagents, may thus be identified without any prior information on the structure of the expected ligand or receptor molecule.
Type:
Grant
Filed:
June 20, 1990
Date of Patent:
March 3, 1998
Assignee:
Affymax Technologies N.V.
Inventors:
William J. Dower, Steven E. Cwirla, Ronald W. Barrett
Abstract: Biotinylation peptides can be fused to other peptides or proteins of interest using recombinant DNA techniques to provide efficient methods for biotinylating the resulting fusion proteins in vivo or in vitro.
Abstract: Camouflage materials that are highly visible to humans but inconspicuous to dichromatic animals are provided. The camouflage materials emit, or simulate emission, of light at or about the neutral point of a dichromatic animal. One kind of camouflage material contains a coloring agent, which limits photopic light emissions from the material to occur at or about the neutral point. Another kind of camouflage material contains at least two coloring agents, which limit photopic light emissions to at least two bands of wavelengths. The respective proportions and spectral properties of these coloring agents are chosen so that the combination of photopic light emitted by camouflage materials incorporating them simulates the appearance of monochromatic light at or about the neutral point.
Type:
Grant
Filed:
February 16, 1993
Date of Patent:
April 25, 1995
Assignee:
Ocutech, Inc.
Inventors:
Jay Neitz, Don H. Anderson, Lincoln V. Johnson, Gregory S. Hageman
Abstract: The invention provides improved methods of prenatal diagnosis that can be performed earlier in pregnancy, and/or with greater safety, and/or rapidity, and/or with greater accuracy than conventional methods. A volume of amniotic fluid containing fetal cells is extracted from a pregnant woman, and the fetal T-cells are propagated in a culture medium comprising one or more cytokines. The fetal T-cells are then diagnosed for genetic defects.
Abstract: A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a fusion protein comprised of a DNA binding protein and a random peptide and also contain a binding site for the DNA binding protein can be used to screen for novel ligands. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand and to the recombinant DNA vector through the DNA binding protein.
Abstract: A method and device for measuring the binding affinity of a receptor to a ligand. According to one aspect of the invention, arrays of polymers are synthesized or immobilized on a substrate (212). The array of polymers is exposed to a fluorescently-labelled receptor in solutions of varying concentration. The fluorescence intensity of the labelled receptor is measured by way of, e.g., a photon counter using a confocal microscope (316). Binding affinity is determined through analysis of the relationship between fluorescence intensity and the solution concentration of the receptor. On-rates are measured as a kinetic increase in surface fluorescence intensity, and the on-rate constant rate extracted from fits to the data.
Abstract: The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human .beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.
Type:
Grant
Filed:
February 19, 1992
Date of Patent:
May 24, 1994
Assignee:
Scripps Research Institute
Inventors:
Per A. Peterson, Michael Jackson, Pierre Langlade-Demoyen